By Fineline Cube 
ChemPartner Pharmatech Co., Ltd. (SHE: 300149) announced that its wholly‑owned subsidiary, Beihai ChemPartner Venture Capital Co., Ltd., has entered into an agreement with Shenzhen Toposcend Capital and several limited partners to create the Shenzhen Luohu Toposcend‑ChemPartner Medical Industry Partnership (Limited Partnership), herein referred to as “the Fund.”
Fund Structure & Capital Commitment
- Total Committed Capital – RMB 200 million (≈ $28 million USD).
- ChemPartner Contribution – RMB 58 million, representing 29 % of the total commitment.
- Partner Mix – The Fund is backed by Toposcend and a consortium of institutional investors, providing a diversified capital base.
Investment Focus
The Fund will invest exclusively in the healthcare sector, with a primary emphasis on innovative pharmaceuticals and, to a lesser extent, cutting‑edge medical devices. Key investment themes include:
- Early‑stage biotech with high‑barrier‑to‑entry drug candidates.
- Platform technologies that accelerate drug discovery and development.
- Next‑generation diagnostics and digital health solutions.
Operating Horizon
The partnership’s lifespan is seven years from the date of establishment, aligning with typical venture‑capital fund cycles and allowing sufficient time to develop portfolio companies through to commercialization or exit.
Strategic Rationale
- ChemPartner’s Expertise – Leveraging ChemPartner’s extensive R&D pipeline and domestic regulatory experience to accelerate product development.
- Toposcend’s Capital Network – Toposcend brings deep investment expertise and a robust network of limited partners, enhancing deal sourcing and portfolio support.
- Synergy in China’s Innovation Ecosystem – The Fund is positioned to tap China’s rapidly expanding biotech market, benefiting from favorable policy support and a growing talent pool.
Next Steps
- Fundraising Completion – All capital commitments are expected to be finalized by Q1 2026.
- Deal Sourcing – The Fund will begin sourcing investments in Q2 2026, targeting companies with breakthrough therapeutic potential.
- Portfolio Management – ChemPartner will lead due diligence and operational support, while Toposcend will provide strategic oversight and governance.-Fineline Info & Tech